From: Prenatal care utilization in pregnant women who consider but do not have abortions
Contemplators n (%) | Non-Contemplators n (%) | P-valuea | Adjusted odds ratiob (95% CI) | |
---|---|---|---|---|
Total, n = 277 | n = 94 | n = 183 | ||
Prenatal visit attendance | ||||
High (80% or more) | 60 (63.8%) | 126 (68.9%) | 0.40 | 1.1 (0.47 – 2.42) |
High medium (60%-80%) | 16 (17.0%) | 41 (22.4%) | 0.29 | 0.7 (0.27 – 1.76) |
Medium (40%-60%) | 9 (9.6%) | 13 (7.1%) | 0.47 | 1.0 (0.20 – 5.01) |
Low medium (20%-40%) | 3 (3.2%) | 2 (1.1%) | 0.21 | 0.8 (0.05 – 14.86) |
Low (20% or lower) | 6 (6.4%) | 1 (0.5%) | < 0.01 | 7.5 (0.58 – 97.75) |
First appointment by 12 weeks | 20 (21.3%) | 151 (82.5%) | < 0.01 | 0.3 (0.13 – 0.79) |
Aneuploidy screening/genetic testing | 59 (62.8%) | 159 (84.2%) | < 0.01 | 0.7 (0.27 – 2.06) |
Carrier screening | 38 (40.4%) | 96 (52.5%) | 0.58 | 0.6 (0.30 – 1.36) |
Sexually transmitted vaginal infection screening | 91 (96.8%) | 146 (79.8%) | < 0.01 | 1.3 (0.22 – 6.92) |
Infectious serology screening | 90 (4.3%) | 175 (4.4%) | 0.96 | 0.2 (0.02 -1.00) |
Blood Panel | 75 (79.8%) | 179 (97.8%) | < 0.01 | 0.7 (0.13 – 3.83) |
1-hour glucose tolerance test | 73 (77.7%) | 169 (92.3%) | < 0.01 | 0.4 (0.12 – 1.61) |
Influenza immunization | 57 (60.6%) | 121 (66.1%) | 0.37 | 0.8 (0.34 – 1.95) |
Tdap immunization | 76 (80.9%) | 110 (60.1%) | < 0.01 | 7.8 (2.53 – 23.83) |
Pap smear screening | 87 (92.6%) | 166 (90.7%) | 0.61 | 2.1 (0.54 – 8.27) |
Cervical length screening | 70 (74.5%) | 151 (82.5%) | 0.11 | 0.8 (0.35 – 2.18) |
Group B streptococcus screening | 79 (84.0%) | 164 (89.6%) | 0.18 | 0.7 (0.20 – 2.65) |
Anatomic ultrasound completed | 62 (66.0%) | 131 (71.6%) | 0.62 | 0.9 (0.39 – 2.25) |
Antepartum contraception counseling | 73/88 (83.0%) | 94/109 (86.2%) | 0.52 | 0.9 (0.24 – 3.24) |
Antepartum breastfeeding anticipatory guidance | 75/88 (85.2%) | 94/106 (88.7%) | 0.48 | 0.6 (0.17 – 2.25) |